Traci S. Umberger, General Counsel and Chief Administrative Officer of Kestra Medical Technologies, Ltd., filed a Form 4 on October 29, 2026, disclosing a stock option exercise and same-day sale of 30,000 common shares on October 27, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Umberger acquired 30,000 common shares on October 27, 2026, via option exercise (transaction code M) at an exercise price of $17 per share.
  • Same-day sale: All 30,000 acquired shares were sold on October 27, 2026, at a weighted average price of $30.0294, with individual sale prices ranging from $30.0000 to $30.4202.
  • 10b5-1 plan: The filing states both transactions were executed pursuant to a scheduled Rule 10b5-1 trading plan adopted on July 21, 2026.
  • Remaining share ownership: Following the transactions, Umberger directly beneficially owned 195,825 common shares.
  • Remaining options: Umberger holds 411,000 options following the reported exercise, of which 365,919 were fully vested as of the filing date, with 45,081 vesting in equal monthly installments through March 6, 2027.
  • Issuer: Kestra Medical Technologies, Ltd., traded on NASDAQ:KMTS.

Umberger's October 2026 Option Exercise and Share Sale at Kestra Medical

According to the Form 4 filing, Traci S. Umberger, who serves as General Counsel and Chief Administrative Officer and is also identified as a Director of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), carried out two linked transactions on October 27, 2026. First, she exercised options to acquire 30,000 common shares at an exercise price of $17 per share (transaction code M). Immediately following, she disposed of the same 30,000 shares (transaction code S) at a weighted average sale price of $30.0294, with the range of individual sale prices spanning $30.0000 to $30.4202. The filing notes that detailed per-price information is available upon request from the reporting person.

The filing states that both the exercise and the sale were conducted as a scheduled transaction under a Rule 10b5-1 trading plan that Umberger adopted on July 21, 2026. As a result of these transactions, Umberger's direct beneficial ownership of common shares decreased from 225,825 to 195,825. Her remaining options position of 411,000 reflects the exercise of the 30,000 options, with the filing disclosing that 365,919 of the remaining options were fully vested as of the filing date. The remaining 45,081 options are described as vesting in equal monthly installments through March 6, 2027, and the options carry an expiration date of March 6, 2035.

The Form 4 was signed by Traci S. Umberger and dated October 29, 2026. No amendment to a prior filing was indicated.

What Was Disclosed

The filing reported a Rule 10b5-1-plan-driven exercise of 30,000 options at $17 and a same-day sale of those shares at a weighted average of $30.0294, leaving Umberger with direct ownership of 195,825 common shares and 411,000 remaining options in Kestra Medical Technologies, Ltd.